

Supplementary Table 1. Baseline characteristics comparing African-American treatment naïve participants to other African-American participants.

	Treatment naïve participants	Other participants	p-value
Sample size (n,%)	1,131 (9.0)	11,389 (91.0)	
AT BASELINE			
Treatment groups:			0.57
Chlorthalidone	412 (36.4)	4,068 (35.7)	
Lisinopril	240 (21.2)	2,405 (21.1)	
Amlodipine	225 (19.9)	2,465 (21.6)	
Doxazosin	254 (22.5)	2,451 (21.5)	
Age, mean (SD)	65.7 (8.2)	66.2 (7.7)	0.04
Women, n (%)	557 (49.6)	6,283 (55.2)	0.0001
SBP in mmHg, mean (SD)	157.1 (12.8)	145.2 (15.8)	0.0001
DBP in mmHg, mean (SD)	90.0 (9.6)	84.2 (10.1)	0.0001
Eligibility risk factors:			
BMI, mean (SD), kg/m ²	29.4 (6.5)	30.5 (6.8)	0.0001
Type 2 diabetes, n (%)	310 (27.4)	4,608 (40.5)	0.0001
Current cigarette smoker, n (%)	409 (36.2)	2,762 (24.3)	0.0001
HDL cholesterol <35 mg/dL, n (%)	46 (4.1)	729 (6.4)	0.002
LVH by electrocardiogram, n (%)	322 (28.5)	2,750 (24.2)	0.001
Fasting glucose, mg/dL	121.7 (63.9)	127.0 (63.5)	0.03
Total cholesterol, mg/dL	217.7 (46.5)	216.9 (43.8)	0.60
HDL cholesterol, mg/dL	52.4 (16.0)	51.7 (15.6)	0.13
LDL cholesterol, mg/dL	139.7 (41.8)	138.6 (39.5)	0.39
Fasting triglyceride, mg/dL	126.0 (94.9)	131.0 (89.4)	0.13
Glomerular filtration rate, mean (SD), mL/min/1.73 m ²	85.3 (21.4)	82.5 (21.7)	0.0001
AT 6 MONTH VISIT			
SBP in mmHg, mean (SD)	139.9 (18.2)	142.3 (18.2)	0.0001
DBP in mmHg, mean (SD)	82.1 (10.7)	82.3 (10.4)	0.52

SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; LVH, left ventricular hypertrophy.

*test of differences between treatment groups: t-test for continuous variables, chi-square for categorical variables.